Lipocine (LPCN) Cash from Investing Activities Growth (3y) (2015 - 2025)
Lipocine (LPCN) Cash from Investing Activities Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -44.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -39.73% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -246.81% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -177.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.84% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.57% |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4.54% |
| Jun 30, 2025 | 5.91% |
| Mar 31, 2025 | -28.48% |
| Dec 31, 2024 | 27.61% |
| Sep 30, 2024 | -9.26% |
| Jun 30, 2024 | 74.56% |
| Mar 31, 2024 | 50.63% |
| Dec 31, 2023 | -20.41% |
| Sep 30, 2023 | 42.42% |
| Jun 30, 2023 | 42.37% |
| Mar 31, 2023 | 12.49% |
| Dec 31, 2022 | 67.01% |
| Sep 30, 2022 | -53.15% |
| Jun 30, 2022 | 66.51% |
| Mar 31, 2022 | 76.55% |
| Dec 31, 2021 | -58.29% |
| Sep 30, 2021 | -40.42% |
| Jun 30, 2021 | -56.51% |
| Mar 31, 2021 | -235.12% |
| Dec 31, 2020 | 70.87% |